This move is archived. Current quotes and coverage live on the stock page.
Get LABS alerts:
Medipharm Labs Corp's stock surged by 7.69% in the last trading session, marking a notable gain for investors.
On the TSX, Medipharm Labs Corp (LABS.TO) saw its stock price rise to CA$0.07. This increase comes alongside positive developments in the company's operations and market position.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$32.04M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+33.3% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
75.2%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.06 – C$0.09 |
| 60 trading days | C$0.07 | C$0.05 – C$0.09 |
| 90 trading days | C$0.07 | C$0.05 – C$0.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Medipharm Labs is making strategic moves that could strengthen its market presence, especially in international markets, which may lead to future growth.
Medipharm Labs Corp's stock jumps 7.69% in one day
With a market cap of CA$29.74 million, the company's stock performance reflects investor optimism following its recent operational advancements.
Bull case
The company reported an 8% annual revenue increase and has successfully entered the European medical cannabis market. This expansion could boost revenue further.
Bear case
Despite the recent gains, Medipharm Labs is still operating at a loss. Ongoing market volatility in the cannabis sector could affect future performance.
Recent Performance Highlights
Advertisement
Medipharm Labs Corp's stock price closed at CA$0.07, reflecting a strong performance with a 7.69% increase in a single trading day. This gain is particularly noteworthy considering the company's recent strategic initiatives aimed at expanding its international footprint.
Strategic Developments
The company has made headlines by completing its first shipment to France, marking its entry into the European medical cannabis market. Additionally, an 8% annual revenue increase to CA$45.1 million highlights its growing international medical cannabis revenue, which now makes up over 50% of total revenue.
Market Outlook
While the recent gains are promising, investors should remain cautious. Medipharm Labs continues to navigate a challenging market environment, and its current profit margin is negative. Future performance will depend on the company's ability to capitalize on its recent expansions and manage operational costs effectively.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
